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Background
HIV-1 prevention methods, like a prophylactic vaccine
and/or microbicides, are urgently needed. Since the ideal
immunogen is as yet undefined and given the role of the
envelope protein (Env) in the entry process, investigation
of the Env structure-function relation is necessary. In this
context resistance towards a promising candidate micro-
bicide M48-U1, a CD4 mimetic mini protein, was evalu-
ated.
Methods
Resistance to M48-U1 was obtained by culturing virus in
the presence of increasing concentrations of the com-
pound. When the degree of resistance was considered suf-
ficient (fold change in IC50 of >10000), genotyping was
performed. Additionally, phenotyping was done by test-
ing the sensitivity towards other CD4 binding site
(CD4bs) inhibitors in a TZM-bl based assay. Furthermore,
the 3D structure of Env's of resistant viruses was modelled
using the software application PyMol.
Results
Resistance to M48-U1 was induced in three subtype B
viruses (BaL, SF162 and a biological cloned virus VI943-
3). All resistant viruses differ in only one amino acid from
their respective controls: S375, situated in the highly con-
served Phe43 cavity of the CD4bs, is mutated into an
arginine. Arginine, as a complex amino acid, is predicted
to fill the Phe43 cavity, thereby abrogating the binding of
M48-U1 yet still allowing binding of the CD4 receptor.
Interestingly, although the viruses belong to the same sub-
type and exhibit the same mutation, their phenotypic out-
comes are different. Cross-resistance towards some CD4bs
inhibitors is observed, but with a different spectrum for
the different viruses. Also, the earlier, less potent mini pro-
tein M48, is still active against some but not all of these
viruses.
Conclusion
In all viruses the same mutation (S375 R) was induced by
M48-U1. However, it is clear that the active site is not the
sole determinant of the phenotype, as viruses with the
same mutation exhibit different cross-resistance patterns.
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